BRIEF-Resverlogix announces positive recommendation from data safety monitoring board for Apabetalone phase 3 study
Aug 11 (Reuters) - Resverlogix Corp
* Resverlogix announces positive recommendation from data safety monitoring board for phase 3 study of Apabetalone (rvx-208)
* Data review by independent data safety monitoring board resulted in verbal recommendation for Betonmace trial to continue as planned
* Dsmb reviewed available study data and noted that no safety or efficacy concerns were identified Source text for Eikon: Further company coverage:
© Thomson Reuters 2017 All rights reserved.